Ready for a BASE jump? Do not neglect SARS-CoV-2 hospitalization and fatality risks in the middle-aged adult population.

Nathanael Lapidus, MD, PhD^{α×1}; Juliette Paireau, PhD^{α2,3}; Daniel Levy-Bruhl, MD, PhD³; Xavier de Lamballerie, MD, PhD⁴; Gianluca Severi, PhD^{5,6}; Mathilde Touvier, PhD⁷; Marie Zins, MD, PhD^{8,9}; Simon Cauchemez, PhD^{ω2}; Fabrice Carrat, MD, PhD^{ω1}; the SAPRIS-SERO study group⁺

^α: These first authors contributed equally to this article.

^ω: These senior authors contributed equally to this article.

[×]: Corresponding author

⁺: Members of the SAPRIS-SERO study group are listed in the Technical Appendix

Affiliations:

¹ Sorbonne Université, Inserm, Institut Pierre-Louis d'Epidémiologie et de Santé Publique, Département de Santé Publique, Hôpital Saint-Antoine, APHP.Sorbonne Université, Paris, France

² Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France

³ Santé Publique France, French National Public Health Agency, Saint-Maurice, France

⁴ Unité des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU

Méditerranée Infection, 13005, Marseille, France

⁵ Department of Statistics, Computer Science and Applications, University of Florence, Italy

⁶ CESP UMR1018, Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, Villejuif, France

⁷ Sorbonne Paris Nord University, Inserm U1153, Inrae U1125, Cnam, Nutritional Epidemiology

Research Team (EREN), Epidemiology and Statistics Research Center – University of Paris

(CRESS), Bobigny, France

⁸ Paris University, Paris, France

⁹ Paris Saclay University, Inserm UMS 11 Villejuif, France

Running Title: SARS-CoV-2 hospitalization and fatality ratios

Keywords: SARS-CoV-2; COVID-19; Age Specific Death Rate; Adult; France

Abstract — 50 words

Seroprevalence results coupled with surveillance data were used to estimate the SARS-CoV-2 infection hospitalization (IHR) and infection fatality ratios (IFR) in France. IHR and IFR were dramatically high in the very elderly (80-90 years: IHR: 30%, IFR: 11%), but also substantial in middle-aged adults (40-50 years: IHR: 1.2%, IFR: 0.05%).

41 **Text — 744 words**

42 **Introduction**

43 The SARS-CoV-2 infection hospitalization ratio (IHR, probability of hospitalization in
44 infected individuals) and the infection fatality ratio (IFR, probability of death in infected
45 individuals) are critical parameters in public health decision-making regarding prioritization of
46 control measures. However, age- and sex-related estimates are scarce, as they need reliable
47 cumulative estimates of past infections, hospitalizations and deaths. By May 11, 2020, the
48 cumulative number of COVID-19-related hospitalizations and hospital deaths in France reached
49 96,000 and 17,000, respectively. This study estimated the age- and sex-specific IFR and IHR in
50 France for this period based on contemporary SARS-CoV-2 seroprevalence data.

51 **Methods**

52 Data from a seroprevalence study performed in May-June 2020 in 20-to 90-year old
53 subjects were used. This study included subjects from three pre-existing general adult population
54 cohorts from Île-de-France (N=6,348) and Grand Est (N=3,434), two regions of France with the
55 highest incidence of COVID-19 during the first wave of the pandemic. (1) All participants from
56 these cohorts with regular access to online questionnaires were invited to participate in the study
57 and dried-blood spots were collected in a random sample among them. All samples were
58 processed with an ELISA test to detect antibodies directed against the spike protein, and for
59 some of them with an ELISA test to detect antibodies directed against the nucleocapsid protein
60 and a micro-neutralization assay to detect neutralizing antibodies (technical details were reported
61 elsewhere (1)). Serological status was estimated with a multiple imputation approach relying on

participants' age, sex and serological results for all available tests. Seroprevalence estimates were calibrated by generalized raking in relation to census data from the general adult population, excluding nursing home residents who were not part of the cohort target population. The cumulative numbers of hospital admissions and deaths for COVID-19 were obtained from the SI-VIC database, the national exhaustive inpatient surveillance system used during the pandemic. Patients from nursing homes were removed from these counts. Since the median date of sample collection in the serosurvey was May 14, hospital admissions and deaths were considered up to May 6 and May 13 to account for estimated 11- and 19- day delays from infection to hospitalization and seroconversion, respectively, (2,3) and an estimated 7-day delay from hospitalization to death (SI-VIC data (4)). We report IHR and IFR by sex and 10-year age class. Multivariable random-effect meta-regression models were fitted to estimate the relative risks (RR) of hospitalization and death according to age and sex, using age class as a continuous covariate.

Results

The overall estimated IHR and IFR in the French adult population (excluding nursing homes) were 3.2% (95% confidence interval (CI): 2.8, 3.6) and 0.58% (95% CI: 0.52, 0.65), respectively. We found a strong log-linear relationship between age and the risk of hospitalization or death, corresponding to an exponential increase in risk with age (Figure). The estimated IHR in 20-30, 40-50, 60-70 and 80-90-year-old subjects was 0.46% (95% CI: 0.30, 0.72), 1.2% (95% CI: 0.96, 1.4), 6.9% (95% CI: 5.3, 9.0) and 30% (95% CI: 10, 99), respectively (RR: 2.1 (95% CI: 1.9, 2.3) per 10-year increase). The estimated IFR in these same age groups was 0.0077% (95% CI: 0.0050, 0.012), 0.050% (95% CI: 0.041, 0.060), 1.0 (95% CI: 0.81, 1.4)

and 11% (95% CI: 3.6, 35), respectively (RR: 3.8 (95% CI: 2.4, 4.2) per 10-year increase). Both IHR and IFR were higher in men than in women for all age classes: RR: 1.5 (95% CI: 1.1, 2.1) and 2.5 (95% CI: 1.8, 3.5), respectively.

Discussion

We identified an overall IHR of 3.2% and an IFR of 0.58% in the adult population, excluding those in nursing homes. Though these ratios may be underestimated in the elderly as nursing home residents are likely to experience poorer outcomes, our estimates are in line with earlier models (3) and various age-specific IFR estimates, worldwide. (5) The IFR exponentially increases with age (doubling every 5.2 years) and is higher in men. Both IHR and IFR were dramatically elevated in the very elderly but this should not obscure substantial estimates in the young or middle-aged adult population. For example, in 20- to 30-year-old adults, the risk of death is 8 times that of a skydiving jump (1 per 100,000 jumps (6)) and in 40 to 50-year-olds, this risk of death is close to that of a BASE jump (1 to 2 per 1000 jumps (6)). From a public health perspective, these findings support the need for comprehensive preventive measures to help reduce the spread of the virus, even in young or middle-aged adults.

References

1. Carrat F, Lamballerie X de, Rahib D, Blanche H, Lapidus N, Artaud F, et al. Seroprevalence of SARS-CoV-2 among adults in three regions of France following the lockdown and associated risk factors: a multicohort study. medRxiv. 2020 Sep 18;2020.09.16.20195693.
2. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020 Mar 28;
3. Salje H, Kiem CT, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the burden of SARS-CoV-2 in France. Science. 2020 Jul 10;369(6500):208–11.
4. Courtejoie N, Dubost C-L. Parcours hospitalier des patients atteints de la Covid-19 lors de la première vague de l'épidémie - Ministère des Solidarités et de la Santé. Direction de la Recherche, des Études, de l'Évaluation et des Statistiques; 2020 Oct. Report No.: 67.
5. O'Driscoll M, Dos Santos GR, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2020 Nov 2;1–9.
6. Wingsuiting death and risk statistics - infographic danger percentage. [cited 2020 Oct 16]. <http://www.wingsuitfly.com/risk/4572000812>

Address for correspondence: Nathanael Lapidus, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Faculté de Médecine Sorbonne Université, 27 rue Chaligny, 75571 Paris Cedex 12, France; email: nathanael.lapidus@inserm.fr

Funding

The SAPRIS-SERO study was supported by Agence Nationale de la Recherche (ANR), #ANR-10-COHO-06, Fondation pour la Recherche Médicale (#20RR052-00), Inserm (Institut National de la Santé et de la Recherche Médicale, #C20-26.

The authors declare no competing interest.

Ethics approval

The SAPRIS-SERO study was approved by the Sud-Méditerranée III ethics committee (approval #20.04.22.74247) and electronic informed consent was obtained from all participants for DBS testing.

Figure legends

Figure: Infection hospitalization ratio and infection fatality ratio with 95% confidence intervals, by age class and sex, estimated from seroprevalence data in France (logarithmic scale). Panel A: Infection hospitalization ratio. Panel B: Infection fatality ratio

A

Infection hospitalization ratio

B

Infection fatality ratio

Female Male